ALVIN E DAVIS, M.D.
Medical Practice at Huntington Ave, Boston, MA
License number
Massachusetts 43511
Category
Medical Practice
Type
Pediatrics
Address
Address
800 Huntington Ave, Boston, MA 02115
Phone
(617) 278-3379
Professional information
Alvin Ezra Davis, Boston MA
Specialties:
Pediatrics, Pediatric Nephrology, Allergy & Immunology, Clinical & Laboratory Immunology
Work:
Ctr For Blood Research
800 Huntington Ave, Boston, MA 02115
800 Huntington Ave, Boston, MA 02115
Education:
University of Illinois at Chicago (1971)
Dr. Alvin E Davis - MD (Doctor of Medicine)
Hospitals:
1340 Soldiers Field Rd, Brighton 02135
CENTER FOR BLOOD RESEARCH
800 Huntington Ave, Boston 02115
1340 Soldiers Field Rd, Brighton 02135
CENTER FOR BLOOD RESEARCH
800 Huntington Ave, Boston 02115
CENTER FOR BLOOD RESEARCH
800 Huntington Ave, Boston 02115
1340 Soldiers Field Rd, Brighton 02135
CENTER FOR BLOOD RESEARCH
800 Huntington Ave, Boston 02115
Education:
Medical Schools
University of Illinois At Chicago / College of Medicine
Graduated: 1971
University of Illinois At Chicago / College of Medicine
Graduated: 1971
Alvin Ezra Davis, Boston MA
Specialties:
Pediatrician
Address:
800 Huntington Ave, Boston, MA 02115
1340 Soldiers Field Rd, Boston, MA 02135
1340 Soldiers Field Rd, Boston, MA 02135
Methods For Treating And Preventing Sepsis Using Modified C1 Inhibitor Or Fragments Thereof
US Patent:
2005028, Dec 29, 2005
Filed:
Mar 24, 2005
Appl. No.:
11/090915
Inventors:
Alvin Davis - Boston MA, US
Dongxu Liu - Brookline MA, US
Dongxu Liu - Brookline MA, US
Assignee:
CBR Institute for Biomedical Research - Boston MA
International Classification:
A61K038/17
US Classification:
514008000
Abstract:
The present invention is based, at least in part, on the discovery that the amino terminal domain and the N-linked carbohydrate contained in the amino terminal of C1INH are required for binding of C1INH to LPS. C1INH has the ability to block the binding of LPS to cells, e.g., macrophages. One aspect of the invention provides a method for treating or preventing sepsis in a subject comprising administering to the subject an effective amount of a composition comprising a modified C1INH polypeptide, thereby treating or preventing sepsis in a subject. In another aspect, the invention provides a method for treating or preventing LPS-mediated inflammation in a subject comprising administering to the subject an effective amount of a composition comprising a modified C1INH polypeptide, thereby treating or preventing LPS-mediated inflammation in a subject. In yet another aspect, the invention provides a method for suppressing the release of LPS-induced TNF-α in a subject comprising administering to the subject an effective amount of a composition comprising a modified C1INH polypeptide, thereby suppressing the release of LPS-induced TNF-α in a subject.
Methods For Modulating Cell-To-Cell Adhesion Using An Agonist Of C1Inh-Type Protein Activity
US Patent:
2006014, Jun 29, 2006
Filed:
Nov 14, 2005
Appl. No.:
11/274009
Inventors:
Alvin Davis - Boston MA, US
Shenghe Cai - Quincy MA, US
Shenghe Cai - Quincy MA, US
Assignee:
CBR Institute for Biomedical Research, Inc. - Boston MA
International Classification:
A61K 38/17
US Classification:
514008000
Abstract:
The present invention is based, at least in part, on the discovery that plasma C1INH contains a sialyl Lewisrelated moiety on its N-glycan and is capable of binding selectin molecules. The invention provides methods for modulating cell-to-cell adhesion or cell migration comprising contacting a cell with a C1INH-type protein or fragment thereof or a nucleic acid encoding a C1INH-type protein or fragment thereof, such that cell-to-cell adhesion is modulated. The invention also provides methods for treating or preventing cell adhesion related disorders in a subject comprising administering to the subject an effective amount of a C1INH-type protein or fragment thereof or a nucleic acid encoding a C1INH-type protein or fragment thereof.